New Stable, High Flux Membrane for Osmotic Distillation of Labile Pharmaceutical

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$99,996.00
Award Year:
2008
Program:
SBIR
Phase:
Phase I
Contract:
1R43GM083375-01
Agency Tracking Number:
GM083375
Solicitation Year:
2008
Solicitation Topic Code:
N/A
Solicitation Number:
PHS2007-2
Small Business Information
COMPACT MEMBRANE SYSTEMS, INC.
COMPACT MEMBRANE SYSTEMS, INC., 335 WATER STREET, NEWPORT, DE, 19804
Hubzone Owned:
Y
Socially and Economically Disadvantaged:
Y
Woman Owned:
Y
Duns:
808898894
Principal Investigator
 STUART NEMSER
 (302) 999-7996
 SNEMSER@COMPACTMEMBRANE.COM
Business Contact
Phone: (302) 999-7996
Email: rtierney@compactmembrane.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): This program will develop a new stable, high flux membrane for osmotic distillation (OD) as a concentration technique for the unprocessed pharmaceutical products from aqueous fermentation broths. Osmotic distillation (O D) is a potentially useful procedure to partially or totally remove water from thermally labile pharmaceutical compounds without exposing the pharmaceutical compounds to undesirable (high) temperatures. The two main issues to be addressed with osmotic dist illation are the need: 1) for a membrane with a very high water transport rate, and 2) for a membrane that avoids wet out. This program addresses both of these issues by using a non-wetting, low surface energy, double-skinned microporous polyvinylidene flu oride (PVDF) membrane that has high wet out resistance (that is, stability) and extraordinarily high water transport. CMS will develop the particular OD application involving dewatering of the enzyme L-lactase dehydrogenase. Tests on the before and after p rotein activity will be done at CMS under the direction of Professor Andrew Zydney at Penn State University. The processing stability of this enzyme is an excellent surrogate to determine the viability of the CMS OD process toward other labile pharmaceutic als. This development, once completed, will represent an application of CMS membrane technology that has considerable significance to pharmaceutical manufacturing.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government